大黄蛰虫丸治疗大鼠免疫性肝纤维化的实验研究
[Experimental study of dahuang zhechong pills in the treatment of immunological liver fibrosis in rats].
作者信息
Sun K, Chen X, Liu W, Chen N, Chu Y, Xie F
机构信息
The First Affiliated Hospital, Hunan Medical College of TCM, Changsha 410007.
出版信息
Zhongguo Zhong Yao Za Zhi. 1998 Aug;23(8):497-9, inside back cover.
OBJECTIVE
To study the effect of DHZC on liver fibrosis.
METHOD
Immuno-injured fibrosis in rats was induced by bovine serum albumin and DHZC was given during and after the model production respectively. Hepatic collagen contents, pathology of liver and serum hyaluronic acid were measured. Colchicine was used as control.
RESULT
It shows that the liver fibrosis rates of the DHZC treated group during and after the model production were 72.7% and 71.2% respectively, while those of the untreated and colchicine group were 92.3%-100%. Compared with the untreated group, there was a remarkable decrease of hepatic collagen contents in the DHZC-treated rats.
CONCLUSION
DHZC have thus been proved helpful in reversing liver fibrosis to some extent.
目的
研究丹黄逐瘀胶囊（DHZC）对肝纤维化的影响。
方法
用牛血清白蛋白诱导大鼠免疫损伤性肝纤维化，在造模期间及造模后分别给予丹黄逐瘀胶囊。检测肝组织胶原含量、肝脏病理及血清透明质酸。以秋水仙碱作为对照。
结果
结果显示，造模期间及造模后丹黄逐瘀胶囊治疗组的肝纤维化发生率分别为72.7%和71.2%，而未治疗组和秋水仙碱组为92.3% - 100%。与未治疗组相比，丹黄逐瘀胶囊治疗的大鼠肝组织胶原含量显著降低。
结论
由此证明丹黄逐瘀胶囊在一定程度上有助于逆转肝纤维化。
Zotero 插件